Production (Stage)
Kiora Pharmaceuticals, Inc.
KPRX
$3.08
-$0.01-0.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | -- | -- | 16.00M |
| Total Other Revenue | -- | 0.00 | -- | 20.00K | -- |
| Total Revenue | -- | 0.00 | -- | 20.00K | 16.00M |
| Cost of Revenue | 2.53M | -3.34M | 1.32M | 906.70K | 1.68M |
| Gross Profit | -2.53M | 3.34M | -1.32M | -886.70K | 14.32M |
| SG&A Expenses | 1.49M | 1.33M | 1.38M | 1.54M | 1.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.06M | 2.51M | 2.70M | 2.44M | 2.79M |
| Operating Income | -2.06M | -2.51M | -2.70M | -2.42M | 13.21M |
| Income Before Tax | -2.07M | -2.16M | -3.41M | -2.22M | 13.45M |
| Income Tax Expenses | 123.00K | 2.07M | -- | -- | -- |
| Earnings from Continuing Operations | -2.19M | -4.22M | -3.41M | -2.22M | 13.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.19M | -4.22M | -3.41M | -2.22M | 13.45M |
| EBIT | -2.06M | -2.51M | -2.70M | -2.42M | 13.21M |
| EBITDA | -2.05M | -2.50M | -2.70M | -2.42M | 13.21M |
| EPS Basic | -0.52 | -1.00 | -0.81 | -0.53 | 4.67 |
| Normalized Basic EPS | -0.27 | -0.30 | -0.37 | -0.31 | 2.92 |
| EPS Diluted | -0.52 | -1.00 | -0.81 | -0.53 | 3.46 |
| Normalized Diluted EPS | -0.27 | -0.30 | -0.37 | -0.31 | 2.16 |
| Average Basic Shares Outstanding | 4.22M | 4.22M | 4.22M | 4.17M | 2.88M |
| Average Diluted Shares Outstanding | 4.22M | 4.22M | 4.22M | 4.17M | 3.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |